Clinical Trials Sponsored by Chengdu Kanghong Pharmaceutical Co., Ltd.

Total 3845 results

Chengdu Kanghong Pharmaceutical Co., Ltd.

Unknown

A Study of Keluo Xin Capsule Compare to Placebo in Terms of Efficacy and Safety in Patients With Diabetic Retinopathy

Moderately Severe to Severe NPDR
Chengdu Kanghong Pharmaceutical Group Co., Ltd.

Recruiting

Phase 1 Study of KH607 Tablets

Healthy

China
Chengdu Kanghong Pharmaceutical Group Co., Ltd.

Unknown

Bioequivalence Study of Bosiqing and ABILIFY Under Fasting/Fed Condition

Bioequivalence

China
Beijing Kanghong Biopharmaceutical Co., Ltd.

Not yet recruiting

Phase 1 Trial of KH801

Advanced Solid Tumors

China
Chengdu Origen Biotechnology Co., Ltd.

Recruiting

Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration

Age-Related Macular Degeneration

United States
Chengdu Origen Biotechnology Co., Ltd.

Recruiting

Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Age-Related Macular Degeneration

China
Chengdu Kanghong Biotech Co., Ltd.

Unknown

An Open, Single-center, Safety and Efficacy Study of Conbercept in Patients With Very Low Vision Secondary to Wet Age-related Macular Degeneration (wAMD) (LAMP)

Very Low Vision Secondary to Wet Age-related Macular Degeneration

China
Chengdu Kanghong Biotech Co., Ltd.

Completed

Conbercept Ophthalmic Injection for Patients With Macular Edema Caused by Branch Retinal Vein Occlusion (BRAVE)

Macular Edema | Branch Retinal Vein Occlusion

China
Chengdu Kanghong Biotech Co., Ltd.

Completed

Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion (CRAVE)

Central Retinal Vein Occlusion | Macular Edema

China
Chengdu Kanghong Biotech Co., Ltd.

Unknown

Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy

Gastric Cancer | Gastroesophageal Cancer
Chengdu Kanghong Biotech Co., Ltd.

Unknown

An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal Neovascularization

Corneal Neovascularization

China
Chengdu Kanghong Biotech Co., Ltd.

Unknown

Phase IV Clinical Trial (STAR Study) Extension Study of Conbercept Ophthalmic Injection for Treatment of Polypoid Choroidal Vasculopathy

Polypoid Choroidal Vasculopathy (PCV)

China
Chengdu Kanghong Biotech Co., Ltd.

Unknown

Safety Evaluation of China Patients: Long-term Treatment Outcome of Conbercept Ophthalmic Injection in Real Word（STONE）

Wet Age-related Macular Degeneration (wAMD)

China
Chengdu Kanghong Biotech Co., Ltd.

Unknown

A Randomized, Double-blind, Multicenter, Sham-controlled, Safety and Efficacy Study of Conbercept in Patients With mCNV (SHINY)

Choroid Neovascularization Secondary to Degenerative Myopia

China
Chengdu Kanghong Biotech Co., Ltd.

Terminated

Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)

Neovascular Age-related Macular Degeneration

United States, Argentina, Australia, Austria, Belgium, Canada, Chile, Colombia, Germany, Hong Kong, Lithuania, Mexico, Netherlands, New Zealand, Peru, Philippines, Poland, Portugal, Singapore, Spain, Switzerland, Taiwan
Chengdu Kanghong Biotech Co., Ltd.

Terminated

Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2)

Neovascular Age-related Macular Degeneration

United States, Bulgaria, China, Czechia, Denmark, France, Hungary, Israel, Italy, Latvia, Slovakia, United Kingdom
Chengdu Kanghong Biotech Co., Ltd.

Unknown

The Efficacy Assessment of Intravitreal Injection of Conbercept in Patients With Polypoidal Choroidal Vasculopathy (PCV) (STAR)

Polypoidal Choroidal Vasculopathy (PCV)

China
Chengdu Kanghong Biotech Co., Ltd.

Unknown

Safety and Efficacy Study of Conbercept in Diabetic Macular Edema (DME) (Sailing)

Diabetic Macular Edema

China
Chengdu Kanghong Biotech Co., Ltd.

Unknown

Efficacy and Safety of Conbercept in Macular Edema Secondary to Retinal Vein Occlusion (FALCON)

Retinal Vein Occlusion

China
Sichuan Jishengtang Pharmaceutical Co., Ltd.

Not yet recruiting

Randomized Clinical Trial of Shugan Jieyu Capsule in Generalized Anxiety Disorder

Generalized Anxiety Disorder
Sichuan Honghe Biotechnology Co., Ltd.

Recruiting

Phase 1 Trial of KH617

Advanced Solid Tumors

China
Chengdu Kanghong Biotech Co., Ltd.
Guangzhou Keli Medical Research Co., Ltd.

Enrolling by invitation

Real World Study of the Effectiveness and Safety of Conbercept Ophthalmic Injection in the Treatment of Retinopathy of Prematurity - Multicenter, Retrospective and Observational Study Based on Real World Data

Retinopathy of Prematurity

China
Chengdu Kanghong Biotech Co., Ltd.
University of Wisconsin, Madison

Completed

A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD (PHOENIX)

Neovascular Age-related Macular Degeneration

China
Chengdu Brilliant Pharmaceutical Co., Ltd.

Not yet recruiting

Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus
Chengdu Brilliant Pharmaceutical Co., Ltd.

Not yet recruiting

The Efficacy and Safety of Esketamine in Elective Laparoscopic Surgery

Laparoscopy | Anesthesia, Intravenous

China
Dalian Holley Kingkong Pharmaceutical Co., Ltd

Unknown

Blood Brain Barrier Penetration and Pharmacokinetics of the Elemene in Malignant Patients.

Cancer

China
Jiangsu Aidea Pharmaceutical Co., Ltd
Chengdu Aidea Pharmaceutical Technology Co., Ltd

Recruiting

Single Ascending Dose, Food Effects and Drug-Drug Interactions of ACC017 Tablets in Healthy Adult Participants

Healthy Adult Participants

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Nasopharyngeal Carcinoma | Non-small Cell Lung Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies

Solid Tumor | Gynecological Malignant Tumor

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer

Breast Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Not yet recruiting

A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Not yet recruiting

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer

HR+HER2- Breast Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Not yet recruiting

A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

HER2-positive Breast Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies

Gynecological Malignancies

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies

Cervical Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Not yet recruiting

A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Not yet recruiting

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

Triple-Negative Breast Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies

Non-hodgkin's Lymphoma

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors

Solid Tumor | Urinary System Tumor

China
Fujian Shengdi Pharmaceutical Co., Ltd.

Not yet recruiting

To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese

Overweight or Obesity

China
Shanghai Shengdi Pharmaceutical Co., Ltd

Not yet recruiting

A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients

Non-squamous Non-small Cell Lung Cancer

China
Fujian Shengdi Pharmaceutical Co., Ltd.

Active, not recruiting

Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects

Type 2 Diabetes

China
Fujian Shengdi Pharmaceutical Co., Ltd.

Active, not recruiting

Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes

Overweight or Obesity

China
Fujian Shengdi Pharmaceutical Co., Ltd.

Completed

A Relative Bioavailability Study of HRS9531 in Healthy Subjects

Type 2 Diabetes

China
Fujian Shengdi Pharmaceutical Co., Ltd.

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS3797 in Healthy Subjects

Skeletal Muscle Relaxation

China
Fujian Shengdi Pharmaceutical Co., Ltd.

Completed

A Study of Remimazolam Tosilate for Sedation in the ICU

Sedation in the ICU

China
Fujian Shengdi Pharmaceutical Co., Ltd.

Not yet recruiting

HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection Fraction

Heart Failure With Preserved Ejection Fraction

Clinical Trials Sponsored by Chengdu Kanghong Pharmaceutical Co., Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations